2741-06-2

Basic information

• Product Name: 1-ETHYL-3-PHENYL-2-THIOUREA
• Synonyms: 1-Ethyl-3-phenylthiocarbamide;1-Ethyl-3-phenylthiourea;1-Ethyl-3-phenyl-thiourea;N-Phenyl-N'-ethylthiourea;Thiourea,N-ethyl-N’-phenyl-;Urea, 1-ethyl-3-phenyl-2-thio-;Urea,1-ethyl-3-phenyl-2-thio-;PHENYLETHYLTHIOUREA
• CAS NO: 2741-06-2
• Molecular Formula: C₉H₁₂N₂S
• Molecular Weight: 180.27
• Mol File: 2741-06-2.mol
• Article Data: 11

Chemical Properties

• Melting Point: 102-104°C
• Boiling Point: 264.9°Cat760mmHg
• Flash Point: 114°C
• Appearance: /
• Density: 1.157g/cm³
• Vapor Pressure: 0.00944mmHg at 25°C
• Refractive Index: 1.638
• CAS DataBase Reference: 1-ETHYL-3-PHENYL-2-THIOUREA(CAS DataBase Reference)
• NIST Chemistry Reference: 1-ETHYL-3-PHENYL-2-THIOUREA(2741-06-2)
• EPA Substance Registry System: 1-ETHYL-3-PHENYL-2-THIOUREA(2741-06-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 2741-06-2(Hazardous Substances Data)

Usage

General Description

1-ETHYL-3-PHENYL-2-THIOUREA is a chemical compound that is primarily used in the pharmaceutical industry. It is a thiourea derivative with a molecular formula of C9H12N2S and a molecular weight of 184.27 g/mol. 1-ETHYL-3-PHENYL-2-THIOUREA is known for its potential therapeutic effects, particularly in the treatment of various medical conditions such as cancer, diabetes, and infectious diseases. It has also been studied for its antimicrobial, antifungal, and antiviral properties. Research has shown that 1-ETHYL-3-PHENYL-2-THIOUREA may have potential as an anticancer agent due to its ability to inhibit certain enzymes and cell processes associated with cancer growth and progression. Additionally, it has been investigated for its potential role in regulating glucose metabolism and insulin secretion in the treatment of diabetes. Further studies are ongoing to explore the full range of potential applications for this compound in the field of pharmaceuticals and medicine.

InChI:InChI=1/C9H12N2S/c1-2-10-9(12)11-8-6-4-3-5-7-8/h3-7H,2H2,1H3,(H2,10,11,12)

Upstream product

• 103-72-0 phenyl isothiocyanate 
• 75-04-7 ethylamine 
• 542-85-8 Ethyl isothiocyanate 
• 100-65-2 N-Phenylhydroxylamine 
• 5700-43-6 silicon tetranilide 
• 18954-89-7 silicic acid dianilide-bis-ethylphenylthioureide 
• 6852-54-6 N-(benzylidene)ethylamine 
• 62-53-3 aniline 

Downstream Products

• 28291-69-2 2-ethylaminobenzothiazole 
• 861616-27-5 N-ethyl-N'-(2,4-dinitro-phenyl)-N-nitro-urea 
• 1096570-91-0 3-ethyl-2-(N-benzylimino)-5-methyl-4-phenyl-1,3-thiazoline 
• 75-04-7 ethylamine 
• 102-08-9 N,N-diphenylthiourea 
• 63500-85-6 3-ethyl-2-(phenylimino)thiazolidin-4-one 
• 1206103-05-0 4-(3-ethylthioureido)benzenesulfonic acid 
• 65573-40-2 cis-[Pt(phenylethylthiourea)(pyridine)Cl₂] 

Relevant articles and documents

Synthesis, spectral, thermal and structural characterization of a hexanuclear copper(I) cluster and a cobalt(III) complex of 1-ethyl-3-phenyl-thiourea

1-Ethyl-3-phenyl-thiourea (Heptu, 1) forms a hexanuclear complex, [Cu6(eptu)6] (2), and a mononuclear complex, [Co(eptu)3] (3), which have been characterized with the aid of elemental analyses, IR, magnetic susceptibility

Antileishmanial thioureas: Synthesis, biological activity and in Silico evaluations of new promising derivatives

Leishmaniasis is a neglected tropical disease caused by protozoan parasites belonging to the genus Leishmania. Currently, the drugs available for treatment of this disease present high toxicity, along with development of parasite resistance. In order to overcome these problems, efforts have been made to search for new and more effective leishmanicidal drugs. The aim of this study was to synthesize and investigate the leishmanicidal effect of N,N′-disubstituted thioureas against Leishmania amazonensis, with evaluation of their in silico pharmacokinetics and toxicity profiles. Our results showed that different thioureas could be obtained in high to moderate yields using simple reaction conditions. Nine thiourea derivatives (3e, 3i, 3k, 3l, 3p, 3q, 3v, 3x and 3z) were active against parasite promastigotes (IC50 21.48–189.10μM), with low cytotoxicity on mice peritoneal macrophages (CC50>200μM), except for thiourea 3e (CC50=49.22μM). After that, the most promising thioureas (3k, 3l, 3p, 3q and 3v) showed IC50 ranging from 70 to 150μM against L. amazonensis amastigotes in infected macrophages. Except for thiourea 3p, the leishmanicidal activity of the derivatives were independent of nitric oxide (NO) production. Thioureas 3q and 3v affected promastigotes cell cycle without disturbing the mitochondrial membrane potential. Furthermore, our derivatives showed satisfactory theoretical absorption, distribution, metabolism, excretion, toxicity (ADMET) properties. These data indicate that thiourea derivatives are good candidates as leading compounds for the development of new leishmanicidal drugs.

Synthesis of thiazolidines via regioselective addition of unsymmetric thioureas to maleic acid derivatives

A wide range of unsymmetric thioureas has been studied in reaction with N-arylmaleimides and maleic anhydride. The regioselectivity of the addition depends not only on steric factors but on both solvent polarity and type of maleic acid derivative (imide o